Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Curis Inc (NQ: CRIS )

8.000 USD -0.400 (-4.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 883,819
Open 8.300
Bid (Size) 8.000 (21)
Ask (Size) 8.100 (37)
Prev. Close 8.400
Today's Range 8.000 - 8.315
52wk Range 1.010 - 17.40
Shares Outstanding 91,596,369
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Curis to Present at Upcoming Healthcare Conferences in September
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive... 
From PR Newswire
Curis Reports Second Quarter 2021 Financial Results
- Presented positive updated data from Phase 1/2 study of CA-4948 monotherapy in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021... 
From PR Newswire

Performance

YTD
-11.41%
-11.41%
1 Month
-0.50%
-0.50%
3 Month
+3.90%
+3.90%
6 Month
-29.89%
-29.89%
1 Year
+669.23%
+669.23%

More News

Read More
Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021
From PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
From GlobeNewswire News Releases
Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes
From PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
From PR Newswire
OMFS's Underlying Holdings Imply 25% Gain Potential
Tags ETFs
From ETF Channel
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
From GlobeNewswire News Releases
Return on Capital Employed Overview: Curis
Tags Market News Benzinga BZI/ROCE
From Benzinga
Commit To Buy Curis At $5, Earn 31.1% Annualized Using Options
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.